CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases

被引:14
|
作者
Gomez-Melero, Sara [1 ]
Caballero-Villarraso, Javier [1 ,2 ]
机构
[1] Maimonides Biomed Res Inst Cordoba, Avda Menendez Pidal S-N, Cordoba 14004, Spain
[2] Univ Cordoba, Fac Med & Nursing, Dept Biochem & Mol Biol, Avda Menendez Pidal S-N, Cordoba 14004, Spain
关键词
CCR6; antibody; therapy; GPCRs; inflammation; immune system; Th17; cells; CHEMOKINE RECEPTOR CCR6; CCR6-EXPRESSING TH17 CELLS; PROTEIN-COUPLED RECEPTORS; REGULATORY T-CELLS; RHEUMATOID-ARTHRITIS; CCL20; AXIS; EXPRESSION; ASSOCIATION; CCR6/CCL20;
D O I
10.3390/antib12020030
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The CC chemokine receptor 6 (CCR6) is a G protein-coupled receptor (GPCR) involved in a wide range of biological processes. When CCR6 binds to its sole ligand CCL20, a signaling network is produced. This pathway is implicated in mechanisms related to many diseases, such as cancer, psoriasis, multiple sclerosis, HIV infection or rheumatoid arthritis. The CCR6/CCL20 axis plays a fundamental role in immune homeostasis and activation. Th17 cells express the CCR6 receptor and inflammatory cytokines, including IL-17, IL-21 and IL-22, which are involved in the spread of inflammatory response. The CCL20/CCR6 mechanism plays a crucial role in the recruitment of these pro-inflammatory cells to local tissues. To date, there are no drugs against CCR6 approved, and the development of small molecules against CCR6 is complicated due to the difficulty in screenings. This review highlights the potential as a therapeutic target of the CCR6 receptor in numerous diseases and the importance of the development of antibodies against CCR6 that could be a promising alternative to small molecules in the treatment of CCR6/CCL20 axis-related pathologies.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases
    Laudisi, Federica
    Dinallo, Vincenzo
    Di Fusco, Davide
    Monteleone, Giovanni
    CURRENT DRUG METABOLISM, 2016, 17 (03) : 303 - 306
  • [22] Pyroptosis in Skeleton Diseases: A Potential Therapeutic Target Based on Inflammatory Cell Death
    Wu, Qian
    Du, Jiacheng
    Bae, Eun Ju
    Choi, Yunjung
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (16)
  • [23] CCR6 has a non-redundant role in the development of inflammatory bowel disease
    Varona, R
    Cadenas, V
    Flores, J
    Martínez-A, C
    Márquez, G
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (10) : 2937 - 2946
  • [24] Inhibition Of Chemokine Receptors CCR1 and CCR6 As Promising Therapies For Autoimmune Diseases Such As Rheumatoid Arthritis and Psoriasis
    Dairaghi, Daniel
    Zhang, Penglie
    Leleti, Manmohan
    Berahovich, Robert
    Ebsworth, Karen
    Ertl, Linda
    Miao, Shichang
    Miao, Zhenhua
    Seitz, Lisa
    Tan, Joanne
    Walters, Matthew
    Wang, Yu
    Powers, Jay
    Schall, Thomas J.
    Jaen, Juan C.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S763 - S763
  • [25] A new hope? Possibilities of therapeutic IgA antibodies in the treatment of inflammatory lung diseases
    Bohlaender, Fabian
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [26] Modulation of the CCR6-CCL20 Axis: A Potential Therapeutic Target in Inflammation and Cancer
    Ranasinghe, Ranmali
    Eri, Rajaraman
    MEDICINA-LITHUANIA, 2018, 54 (05):
  • [27] The ubiquitin proteasome system as a potential therapeutic target for treatment of neurodegenerative diseases
    Opattova, Alena
    Cente, Martin
    Novak, Michal
    Filipcik, Peter
    GENERAL PHYSIOLOGY AND BIOPHYSICS, 2015, 34 (04) : 337 - 352
  • [28] The AHR as a therapeutic target for inflammatory skin diseases
    van den Bogaard, Ellen
    TOXICOLOGY LETTERS, 2017, 280 : S48 - S48
  • [29] Dynamic expression of CCR6 and CCR2 balances homeostatic and inflammatory trafficking of γδT17 cells
    McKenzie, D.
    Kara, E.
    Tyllis, T.
    Bastow, C.
    Fenix, K.
    Gregor, C.
    Kallies, A.
    Nutt, S.
    Comerford, I
    McColl, S.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 151 - 151
  • [30] Myosin Light Chain Kinase: A Potential Target for Treatment of Inflammatory Diseases
    Xiong, Yongjian
    Wang, Chenou
    Shi, Liqiang
    Wang, Liang
    Zhou, Zijuan
    Chen, Dapeng
    Wang, Jingyu
    Guo, Huishu
    FRONTIERS IN PHARMACOLOGY, 2017, 8